Antimicrobial peptides and other potential biomarkers of critical illness in SARS‐CoV‐2 patients with acute kidney injury. AMPAKI‐CoV study

Abstract

AbstractAntimicrobial peptides (AMPs) constitute a complex network of 10–100 amino acid sequence molecules widely distributed in nature. While over 300 AMPs have been described in mammals, cathelicidins and defensins remain the most extensively studied. Some publications have explored the role of AMPs in COVID‐19, but these findings are preliminary, and in vivo studies are still lacking. In this study, we report the plasma levels of five AMPs (LL‐37, α‐defensin 1, α‐defensin 3, β‐defensin 1, and β‐defensin 3), using the ELISA technique (MyBioSource, San Diego, CA, United States, kits MBS2601339 (beta‐defensin 1), MBS2602513 (beta‐defensin 3), MBS703879 (alpha‐defensin 1), MBS706289 (alpha‐defensin 3), MBS7234921 (LL37)), and the measurement of six cytokines (tumor necrosis factor‐α, interleukin‐1β, interleukin‐6, interleukin‐10, interferon‐γ, and monocyte chemoattractant protein‐1), through the magnetic bead immunoassay Milliplex® and the MAGPIX® System (MilliporeSigma, Darmstadt, Germany, kit HCYTOMAG‐60 K (cytokines)), in 15 healthy volunteers, 36 COVID‐19 patients without Acute Kidney Injury (AKI) and 17 COVID‐19 patients with AKI. We found increased levels of α‐defensin 1, α‐defensin 3 and β‐defensin 3, in our COVID‐19 population, when compared to healthy controls, along with higher levels of interleukin‐6, interleukin‐10, interferon‐γ, and monocyte chemoattractant protein‐1. These findings suggest that these AMPs and cytokines may play a crucial role in the systemic inflammatory response and tissue damage characterizing severe COVID‐19. The levels of α‐defensin 1 and α‐defensin 3 were significantly higher in COVID‐19 AKI group in comparison to the non‐AKI group. Furthermore, IL‐10 and the product IL‐10 × IL‐1B showed excellent performance in discriminating AKI, with AUCs of 0.86 and 0.88, respectively. Among patients with COVID‐19, AMPs may play a key role in the inflammation process and disease progression. Additionally, α‐defensin 1 and α‐defensin 3 may mediate the AKI process in these patients, representing an opportunity for further research and potential therapeutic alternatives in the future.